Health Coalition’s Cost-Cutting Pledge Needs Five-Year Target - Orszag
This article was originally published in The Pink Sheet Daily
Pharma’s eventual role in cost reduction remains unclear; FOBs unlikely to yield savings short-term.
You may also be interested in...
The Senate Finance Committee is looking to the pharmaceutical industry to contribute to paying for health care reform in the form of adjustments to Medicaid rebates and the introduction of means testing in Medicare Part D
The White House is expecting a private sector healthcare coalition - including the pharmaceutical industry - to produce details in early June on a pledge to help reduce the annual health care spending growth rate by 1.5 percentage points over the next 10 years
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.